Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$33.70

1.31 (4.04%)

, TEVA

Teva

$31.96

-1.23 (-3.71%)

16:01
07/14/17
07/14
16:01
07/14/17
16:01

AstraZeneca says Soriot to host results presentation on July 27, NY Times says

AstraZeneca (AZN) said that CEO Pascal Soriot will hots a results call with reporters on July 27, after declining to comment on speculation this week that he was leaving the company, the New York Times reports, citing an invitation to reporters. "You are invited to participate in a media teleconference hosted by Pascal Soriot, CEO, to discuss the results," the invitation said, according to the Times. AstraZeneca has refused to comment on a recent report saying Soriot was in talks to join Teva (TEVA), the report notes. Reference Link

AZN

AstraZeneca

$33.70

1.31 (4.04%)

TEVA

Teva

$31.96

-1.23 (-3.71%)

  • 19

    Jul

  • 03

    Aug

  • 30

    Aug

AZN AstraZeneca
$33.70

1.31 (4.04%)

07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
07/13/17
SBSH
07/13/17
NO CHANGE
Target $42
SBSH
Buy
Teva landing Soriot would be 'material positive,' says Citi
Citi analyst Liav Abraham believes Calcalist's report of Teva (TEVA) hiring away AstraZeneca's (AZN) CEO Pascal Soriot has credibility given the "relatively accurate track record" of the Israeli press in the "leaking" of information pertaining to Teva. The news, if confirmed, would be a "material positive" for Teva over the near to medium term, Abraham tells investors in a research note. She believes Soriot would "lend significant credibility" to Teva's turnaround thesis. On the other side, Soriot leaving would increase concerns over the pending outcome of AstraZeneca's MYSTIC trial, which constitutes the dominant near-term driver for the shares, Abraham argues. She has a Buy rating on Teva with a $42 price target. The stock in premarket trading is up 2% to $32.80. AstraZeneca is down 14c to $32.78.
07/13/17
LEER
07/13/17
NO CHANGE
LEER
Outperform
AstraZeneca CEO departure now would have 'terrible' optics, says Leerink
Leerink analyst Seamus Fernandez said the media report that AstraZeneca (AZN) CEO Pascal Soriot may be leaving the company to take over at Teva (TEVA) comes as a "major surprise," adding that while the company would not comment to him on the rumor it also did not outright deny the report. While the news does not appear to be related to the outcome of the MYSTIC trial in non-small cell lung cancer, the optics around such a departure at this would be "terrible" and his loss would be a "clear negative" for AstraZeneca, according to Fernandez, who has an Outperform rating on Astra shares.
07/05/17
SBSH
07/05/17
DOWNGRADE
SBSH
Neutral
GlaxoSmithKline downgraded to Neutral from Buy at Citi
Citi analyst Andrew Baum downgraded GlaxoSmithKline (GSK) to Neutral and lowered his price target for the shares to GBP 17 from GBP 18. The analyst believes the market is underappreciating the slowing of the company's HIV market growth. He prefers shares of AstraZeneca (AZN), Roche (RHHBY) and Bayer (BAYRY) for exposure to Europe.
TEVA Teva
$31.96

-1.23 (-3.71%)

07/05/17
OPCO
07/05/17
NO CHANGE
Target $70
OPCO
Outperform
Neurocrine Ingrezza 'holds steady' after competitor data, says Oppenheimer
Oppenheimer analyst Jay Olson notes that Teva's (TEVA) Austedo could become a competitor to Neurocrine's (NBIX) Ingrezza with a PDUFA date for the tardive dyskinesia indication on August 30, 2017. However, the analyst sees Ingrezza as well positioned and reiterates an Outperform rating and $70 price target on Neurocrine's shares. A key factor to follow beyond the short trials will be real-life performance considering the number needed to treat to observe a 50% AIMS improvement was 5 for Austedo and 4 for Ingrezza, he contends.
06/27/17
WELS
06/27/17
NO CHANGE
WELS
Market Perform
Teva TV-45070 trial miss a 'modest disappointment,' says Wells Fargo
Wells Fargo analyst David Maris said TV-45070 has not been a focus for Teva (TEVA) investors, but he still views the news that the company and partner Xenon Pharmaceuticals' (XENE) Phase 2 trial in post-herpetic neuralgia missed its primary endpoint as a "modest disappointment" given the need for Teva's pipeline to offset the tough generic market and the eventual competition for Copaxone. Maris keeps a Market Perform rating on Teva.

TODAY'S FREE FLY STORIES

FB

Facebook

$144.25

2.06 (1.45%)

, AAPL

Apple

$186.81

-5.42 (-2.82%)

05:36
11/15/18
11/15
05:36
11/15/18
05:36
Periodicals
Facebook CEO ordered staff to use Android phones after Apple criticism, NYT says »

Facebook (FB) CEO Mark…

FB

Facebook

$144.25

2.06 (1.45%)

AAPL

Apple

$186.81

-5.42 (-2.82%)

GOOG

Alphabet

$1,043.53

7.2 (0.69%)

GOOGL

Alphabet Class A

$1,054.06

5.52 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Mar

ABBV

AbbVie

$88.28

0.06 (0.07%)

05:29
11/15/18
11/15
05:29
11/15/18
05:29
Hot Stocks
AbbVie signs DUBs collaboration with Mission Therapeutics »

Mission Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNK

Teekay Tankers

$1.07

0.025 (2.39%)

05:26
11/15/18
11/15
05:26
11/15/18
05:26
Earnings
Teekay Tankers reports Q3 adj. EPS (7c), consensus (10c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ATUS

Altice USA

$17.71

-0.1 (-0.56%)

05:25
11/15/18
11/15
05:25
11/15/18
05:25
Initiation
Altice USA initiated  »

Altice USA initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGP

Teekay LNG

$14.41

0.29 (2.05%)

05:23
11/15/18
11/15
05:23
11/15/18
05:23
Earnings
Teekay LNG reports Q3 adj. EPS 16c, consensus 34c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SUBCY

Subsea 7

$0.00

(0.00%)

05:22
11/15/18
11/15
05:22
11/15/18
05:22
Upgrade
Subsea 7 rating change  »

Subsea 7 upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EXEL

Exelixis

$16.75

0.09 (0.54%)

, IPSEY

Ipsen

$0.00

(0.00%)

05:20
11/15/18
11/15
05:20
11/15/18
05:20
Hot Stocks
Exelixis receives EC approval for Cabometyx tablets »

Exelixis (EXEL) announced…

EXEL

Exelixis

$16.75

0.09 (0.54%)

IPSEY

Ipsen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 27

    Nov

  • 14

    Jan

CTTAY

Continental AG

$0.00

(0.00%)

05:19
11/15/18
11/15
05:19
11/15/18
05:19
Downgrade
Continental AG rating change  »

Continental AG downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

VLEEY

Valeo

$0.00

(0.00%)

05:18
11/15/18
11/15
05:18
11/15/18
05:18
Downgrade
Valeo rating change  »

Valeo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,599.16

-32.52 (-1.99%)

05:14
11/15/18
11/15
05:14
11/15/18
05:14
Recommendations
Amazon.com analyst commentary  »

Amazon shares offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 04

    Dec

ATNX

Athenex

$10.28

-1.38 (-11.84%)

05:08
11/15/18
11/15
05:08
11/15/18
05:08
Upgrade
Athenex rating change  »

Athenex upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

STIM

Neuronetics

$18.58

-3.17 (-14.57%)

05:08
11/15/18
11/15
05:08
11/15/18
05:08
Recommendations
Neuronetics analyst commentary  »

Neuronetics selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVID

Avid

$5.79

0.19 (3.39%)

04:59
11/15/18
11/15
04:59
11/15/18
04:59
Recommendations
Avid analyst commentary  »

Avid price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIN

Linde plc

$153.45

-3.35 (-2.14%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Initiation
Linde plc initiated  »

Linde plc initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QLYS

Qualys

$71.92

-0.09 (-0.12%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
Qualys to hold analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 09

    Jan

PFG

Principal Financial

$48.29

-0.71 (-1.45%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
Principal Financial to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 03

    Dec

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
RBC Capital telecom/data centers analyst to hold a group luncheon »

Telecom & Data…

CNHI

CNH Industrial

$9.81

-0.03 (-0.30%)

, HSY

Hershey

$107.94

-1.24 (-1.14%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
BlackLine to hold a summit »

In The Black 2018:…

CNHI

CNH Industrial

$9.81

-0.03 (-0.30%)

HSY

Hershey

$107.94

-1.24 (-1.14%)

TAP

Molson Coors

$64.75

0.24 (0.37%)

ZEN

Zendesk

$53.12

0.56 (1.07%)

ETP

Energy Transfer Partners

$0.00

(0.00%)

G

Genpact

$29.11

-0.73 (-2.45%)

SAP

SAP

$103.86

0.11 (0.11%)

BL

BlackLine

$38.78

-1.79 (-4.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 26

    Nov

  • 02

    Dec

  • 06

    Dec

  • 06

    Dec

  • 12

    Dec

  • 13

    Dec

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
RBC Capital software analysts to hold a group luncheon »

Software Analysts Hedberg…

MKTX

MarketAxess

$209.85

2.02 (0.97%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
MarketAxess management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

04:55
11/15/18
11/15
04:55
11/15/18
04:55
General news
Retail Sales less autos to be reported at 08:30 »

October Retail Sales less…

04:55
11/15/18
11/15
04:55
11/15/18
04:55
General news
Breaking General news story  »

Minneapolis Federal…

04:55
11/15/18
11/15
04:55
11/15/18
04:55
General news
Breaking General news story  »

Week of 11/9 EIA Natural…

AWI

Armstrong World

$66.00

-1.94 (-2.86%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
Armstrong World management to meet with SunTrust »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 16

    Nov

MGM

MGM Resorts

$25.94

0.2 (0.78%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
MGM Resorts management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 19

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.